Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
The Russian Ministry of Health approves trial of Biocad’s new drug
Since 2020, the company has more than doubled the number of trials.
As published in the state Register of Medicines on February 20, the Ministry of Health of Russia has approved a gene therapy drug trial for haemophilia B. The trial is scheduled to end by mid-2031.
A Phase I/II clinical trial is planned, according to the Register. It will investigate the drug's safety and efficacy when administered in incremental doses via a single intravenous injection.
The trials to be performed on 54 participants, will take place in 13 medical centres across Russia, including Moscow, St. Petersburg, Ufa, Nizhny Novgorod, Samara, Chelyabinsk, Kemerovo, Novosibirsk, Syktyvkar, Kirov, and others.
Biocad announced at the end of 2022 that it is increasing the number of clinical trials of drugs for cancer, autoimmune, and orphan diseases. Since 2020, the company has more than doubled the number of trials.